KOSDAQ large cap
Kolon TissueGene
A Kolon-affiliated biotech developing the osteoarthritis gene therapy Invossa. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
950160.KQ Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21+0%'22+22.2%'23+19.4%'24+145.5%'25+265.9%YTD-14.3%
Money in ▸·
Kolon TissueGene
▸ Money out·
Financials & Segments
- Segments · Gene therapy development (Invossa/TG-C)
Revenue from
No refined links yet.
Pays to
No refined links yet.